Procurement teams focus on features and licensing during selection, but the question that decides long-term cost is what happens when the platform stops fitting. That question usually comes up for the first time during a migration attempt, when the lab discovers that exporting a clean, usable copy of its data is either impossible or more expensive than staying.

This article covers how lock-in builds up inside a commercial LIMS, ELN, or eQMS, the regulatory burden that makes leaving harder than it would be with ordinary business software, and what contract clauses are worth negotiating before signing.

Part 1: How lab software data lock-in builds up

Data lock-in in lab software builds up in layers. The first layer is the schema itself, which belongs to the vendor. Sample types, custom fields, assay definitions, and all the relationships between them live inside a proprietary data model that no other system understands in the same way. Every time a lab configures a workflow inside a commercial LIMS or ELN, it is building a data structure that only the vendor's platform can read correctly. That accumulated configuration is where lock-in starts.

Then there is the export problem. Commercial platforms usually offer a CSV or Excel export, and it sounds like a portability story until you actually run one. The parent-child relationships between records collapse into flat rows and the attachments come out as references to files that are not included. The audit trail lands as a human-readable log the next system cannot ingest as structured data, and custom fields lose the context that made them meaningful. What the lab ends up with is a technically complete export that cannot be loaded into any other platform.

The MHRA acknowledged this problem directly in its 2018 GxP Data Integrity Guidance, which still governs UK GxP environments. The guidance says plainly that full-fidelity migration is sometimes impossible:

Migration to an alternative file format that retains as much as possible of the 'true copy' attributes of the data may be necessary with increasing age of the legacy data. Where migration with full original data functionality is not technically possible, options should be assessed based on risk... It is recognised that the need to maintain accessibility may require migration to a file format that loses some attributes and/or dynamic data functionality (e.g. data interrogation, trending, re-processing etc).

Regulators are saying it in writing: leaving a system sometimes means losing the interactivity of the data itself. Spin Wang, co-founder and CTO of TetraScience, made a similar point from the vendor side in 2023: "Scientific data can be difficult, perhaps impossible, to move outside the vendor's 'walled garden,' restricting how you can use your data." TetraScience sells a scientific data liquidity platform, so the framing helps their business, but the underlying technical claim matches what labs actually see when they try to migrate.

Part 2: Why leaving a regulated lab system is harder than leaving ordinary software

Any lab operating under FDA, EMA, MHRA, or equivalent oversight carries a validation burden that makes migration a completely different exercise from swapping out a CRM. Changing a production system in a GxP environment is a full validation project, and that changes everything about what it costs to leave.

Under ISPE GAMP 5 (Second Edition, 2022), any new system has to pass qualification before it can hold regulated data. In practice that means installation, operational, and performance qualification stages, each documented and approved. The retirement of the old system is its own project: data retention and archival have to be addressed, and the lab needs a defined process for how records will remain retrievable for inspection after the system is gone. None of that is optional for a regulated lab, and none of it shows up in the new vendor's quote.

Audit trail continuity is where lock-in gets concrete. 21 CFR Part 11 section 11.10(e) requires "secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records." An audit trail only means something inside the system that produced it, so when records are moved to a new platform and the old audit trail comes across as a flat text export, an FDA inspector reading a batch record five years later has no way to verify the integrity of the sequence or figure out which fields were changed by whom. The common workaround is to keep the old system running in read-only mode purely for audit retrieval, which means paying for legacy licenses and infrastructure on top of whatever the new implementation already costs.

Records retention extends the same problem over a longer horizon. 21 CFR 11.10(c) requires "protection of records to enable their accurate and ready retrieval throughout the records retention period," and the retention obligations under 21 CFR 312.62 and 21 CFR 211.180 run for years past the end of a study or the release of a batch. If the lab migrates off a vendor and the old export format cannot be opened inside the new system, the lab either keeps the legacy system running for the entire retention window or pays for a migration that preserves ready retrieval, which usually requires vendor cooperation the lab no longer has leverage to get.

Migration itself is the fourth burden. MHRA section 6.8 requires that "data transfer/migration procedures should include a rationale, and be robustly designed and validated to ensure that data integrity is maintained during the data lifecycle." EU Annex 11 section 4.8 says that "if data are transferred to another data format or system, validation should include checks that data are not altered in value and/or meaning during this migration process." The draft 2025 revision of Annex 11 took the original 5-page document out to 19 pages, with significantly more detailed requirements around data migration validation. Whatever the bar used to be for validating a replacement system, it is higher now and still rising.

Part 3: Why labs stay stuck on tools they have outgrown

Put proprietary schemas together with regulatory migration cost and the result is straightforward. Once a lab is fully embedded in a commercial platform, leaving is a multi-year project with uncertain outcomes, and labs stop attempting it. They keep paying for tools that no longer fit because the cost of leaving has become higher than the cost of staying.

Cindy Novak has managed 27 LIMS implementations across a 30-year career in biotech and pharma IT. Speaking at the Veeva R&D and Quality Summit in November 2025, she opened her talk with "LIMS is a four-letter word" and went on to describe how legacy systems "operate in legacy ways that lock QC into tired work processes" and force users to "become experts in data manipulation to get the results they need." Her one-line summary of the industry: "providers don't listen and won't change." That is a senior practitioner talking, and Lab Manager picked up her talk because the frustration she was describing was already familiar to everyone in the room.

The broader picture matches her experience. Deloitte's 2025 Pharma R&D Lab of the Future survey of 104 biopharma executives found 31% of labs are "digitally siloed, relying on multiple electronic lab notebooks and laboratory information management systems with limited integration or automation," and only 11% described their own labs as fully connected and predictive. The Pistoia Alliance 2024 Lab of the Future survey found 59% of respondents cited inability to access data as a core problem and 38% reported their data was not FAIR-compliant. Becky Upton, president of Pistoia Alliance, pointed to cultural barriers, privacy concerns, and a lack of collaboration infrastructure as the reasons labs still cannot use their own data effectively.

The same Pistoia data shows where labs are planning to put money: 62% in AI and machine learning, 37% in cloud platforms, 23% in ELNs, and 20% in LIMS. LIMS and ELN together account for less than a quarter of planned investment, while AI/ML and cloud platforms take the majority. That reading is not the only one. Labs may simply be prioritizing AI and cloud on their own merits. But the low replacement investment in LIMS and ELN is hard to explain if those tools were actually working. That spending pattern looks like labs routing around the systems they already have instead of replacing them, and that is what being stuck looks like. Replacement is too expensive, so the money goes to the layer above.

Part 4: What to check before you sign

If your lab is evaluating a commercial LIMS, ELN, or eQMS, the best protection against lock-in is negotiating the exit before you sign. Vendors will discuss portability while there is still a deal on the table, and they get much less cooperative three years later when a customer is already trying to leave. The clauses below are the ones to confirm in writing.

Schema ownership. When a lab configures custom sample types, custom fields, and the relationships between records inside a commercial LIMS, the question nobody asks during procurement is who owns the resulting data model. Some vendors treat the schema as part of the platform, which means the logic of how your lab operates is tied to their product and leaves with them. Others separate user configuration from product code and give the customer rights to that configuration. This one distinction matters more than any other feature comparison you will do.

Export format and fidelity. "We support CSV export" is not a portability story. Ask the vendor for a test export of a realistic dataset that includes custom fields, parent-child relationships between records, attachment references, and audit trail data, and then check whether the export can be re-imported back into the same system without losing anything. If the vendor's own platform cannot cleanly round-trip its own export, any other system you try to migrate to will lose at least that much.

API access. A documented, versioned API that supports bulk export across all record types is the baseline for integrations that actually save time. Check that the API is part of the base license and is not paywalled behind an enterprise tier that doubles the contract value.

Data portability clause. Write a contractual right of exit into the agreement. The clause should say that if the customer decides to leave, the vendor will deliver a complete export of customer data in a mutually agreed format within a defined period, with 30 to 60 days being a reasonable window. Without this clause, the exit timeline and the export format are both at the vendor's discretion.

Audit trail export. Confirm that the audit trail can be exported in a structured form (JSON or XML) that preserves record identifiers, user actions, timestamps, and the link back to the records being audited. A flat PDF or CSV of the audit log looks complete on the surface and loses the ability to verify continuity against the original records once a new system takes over.

Archive access rights. Ask what happens to your archived data when the contract ends. Some vendors delete archives 30 days after termination, some keep them accessible for a read-only fee, and others require an ongoing archive license that preserves historical data through the retention period. Get the answer in writing before signing.

Schema ownership is the clause to get right. If the vendor owns the data model your lab builds inside their system, there is no way to reconstruct the workflow anywhere else without starting from scratch, and every other portability clause matters less once the schema is gone.

Conclusion

The sticker price is what gets negotiated during a lab software purchase. Lock-in determines long-term cost, and it never appears on a quote. Proprietary schemas, limited export fidelity, the regulatory cost of moving validated records, and the infrastructure cost of keeping legacy systems running for audit retrieval combine to make commercial LIMS, ELN, and eQMS platforms much easier to enter than to leave. The window to negotiate portability into the contract is during the evaluation, while the vendor still has a deal to win, not three years later when the lab is already stuck and the vendor has no reason to cooperate.

At CodePhusion we build custom software for biotech labs partly because of this dynamic. When the schema and the code belong to the lab, changing direction later does not depend on a vendor cooperating with you.

Evaluating a new LIMS or thinking about building your own? CodePhusion builds custom lab software where your lab owns the schema, the codebase, the data, and the exit path. Talk to our team about what that looks like for your workflow.

Frequently Asked Questions

What is data lock-in in lab software?

Data lock-in in lab software is the difficulty of extracting a lab's records, workflows, and configurations from a commercial LIMS, ELN, or eQMS in a form another system can actually use. The schema is proprietary, exports flatten the relationships between records, attachments come out as references without the files, and the audit trail loses its continuity once it leaves the system that produced it. In regulated environments, the validation and compliance cost of moving records between systems makes that problem several times worse.

Why is migrating off a commercial LIMS or ELN so expensive?

Migration in a regulated lab is a full validation project. Any new system has to pass qualification under GAMP 5 before it can hold regulated data, and audit trail and records retention requirements under 21 CFR Part 11 and EU Annex 11 can force labs to keep the legacy system running for years after migration purely for inspection access. The validation work, dual-system maintenance, and vendor cooperation required to execute a clean exit add up to a cost that most labs do not anticipate during procurement.

Does 21 CFR Part 11 apply to migration between systems?

Yes. 21 CFR 11.10(a) requires validation of systems, 11.10(b) requires that systems generate accurate and complete copies of records in human-readable and electronic form, 11.10(c) requires records to remain accurately retrievable throughout the retention period, and 11.10(e) requires secure, computer-generated, time-stamped audit trails. All four create obligations that carry across a migration, and EU Annex 11 section 4.8 adds a parallel requirement that migration be validated to preserve the meaning of the data.

What contract clauses help avoid lock-in in a LIMS purchase?

There are six clauses to negotiate before signing: schema ownership, export format and fidelity, API access with bulk export, a data portability clause with defined exit terms, audit trail export in a structured format, and archive access rights after contract termination. A well-drafted data portability clause specifies the format, the timeline, the scope of data covered, and the vendor's obligations on a clean exit.

How does custom software avoid data lock-in?

Custom software owns its own schema and data format. The lab controls the database, the codebase, the data format, and the infrastructure from the start. Migration to a new tool is still a real project, but it does not depend on a vendor cooperating with the exit, so changing direction later becomes a technical problem the lab can actually solve on its own timeline.

References

• 'GXP' Data Integrity Guidance and Definitions, Revision 1 (March 2018) - UK Medicines and Healthcare products Regulatory Agency
• 21 CFR Part 11: Electronic Records; Electronic Signatures - US Food and Drug Administration
• EU GMP Annex 11: Computerised Systems - European Commission
• EU GMP Annex 11 Draft 2025 Revision - GMP Compliance
• GAMP 5 Guide, Second Edition (July 2022) - International Society for Pharmaceutical Engineering
• Advice from a Growing Biotech on Launching a New LIMS - Lab Manager Magazine, November 2025 (Cindy Novak, Veeva R&D and Quality Summit)
• Future-Proofing Pharma R&D Labs - Deloitte Center for Health Solutions, July 2025
• Lab of the Future 2024 Global Survey - Pistoia Alliance, October 2024
• Do Not Use ELN/LIMS as a Data Layer - Spin Wang, TetraScience, October 2023
• Draft Annex 11 Revision: From Interpretive to Prescriptive Regulation - Technology Networks, 2025

Last updated: April 10, 2026